Drug intelligence / Profile preview

ampicillin sodium + immune globulin

Development stage: Unknown
Lead developer: GC Biopharma
Modality: Small Molecules
Administration: Intravenous, Intramuscular, Subcutaneous

Overview

This is a combination of ampicillin sodium, a broad-spectrum beta-lactam antibiotic in the penicillin class, and immune globulin, a blood product containing antibodies. Ampicillin sodium works by stopping bacterial growth, while immune globulin provides passive immunity. This combination is not a standard fixed-dose combination product but may be administered separately for patients requiring both antimicrobial therapy and immune support.

Targets

FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)PBP (Penicillin-binding protein family)FCGRT (Neonatal crystallizable fragment receptor)

Beyond the preview

Go deeper on ampicillin sodium + immune globulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ampicillin sodium + immune globulin.

Explore the full profile